Omentin-1 and nonfatal ischemic heart disease in postmenopausal women: A population-based study

Endocrine Practice

Volumn 22, Issue 7, 2016, Pages 780-785

  Pourbehi, Mohammad Reza ^a   Zahedi, Talieh ^a   Darabi, Hossein ^a   Ostovar, Afshin ^a   Assadi, Majid ^a   Nabipour, Iraj ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; OMENTIN 1; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; LIPID;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MIDDLE AGED; POSTMENOPAUSE; PREVALENCE; WAIST CIRCUMFERENCE; AGED; BLOOD; MYOCARDIAL ISCHEMIA; STATISTICAL MODEL;

ADIPONECTIN; AGED; BLOOD PRESSURE; CYTOKINES; ELECTROCARDIOGRAPHY; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; LIPIDS; LOGISTIC MODELS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POSTMENOPAUSE;

EID: 85020374361     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP151134.OR     Document Type: Article

References (40)

1. Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005;1732:96-102.
2. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metabol. 2006;290:E1253-E1261.
3. Akbarzadeh S, Nabipour I, Assadi M, et al. The normoglycemic first-degree relatives of patients with type 2 diabetes mellitus have low circulating omentin-1 and adiponectin levels. Cytokine. 2012;58:295-299.
4. Katsi V, Vamvakou G, Lekakis J, et al. Omentin, fat and heart: classical music with new instruments. Heart Lung Circ. 2014;23:802-806.
5. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010;20:143-148.
6. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56:1655-1661.
7. Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011;93:21-25.
8. Yoo HJ, Hwang SY, Hong HC, et al. Implication of circulating omentin-1 level on the arterial stiffening in type 2 diabetes mellitus. Endocrine. 2013;44:680-687.
9. Greulich S, Chen WJ, Maxhera B, et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PloS One. 2013;8:e59697.
10. Tohidi M, Akbarzadeh S, Larijani B, et al. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women. Bone. 2012;51: 876-881.
11. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011;34:307-310.
12. Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008;57:801-808.
13. Zhong X, Zhang HY, Tan H, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011;32:873-878.
14. Shibata R, Ouchi N, Kikuchi R, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219:811-814.
15. Onur I, Oz F, Yildiz S, et al. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women. Angiology. 2014;65:896-900.
16. Narumi T, Watanabe T, Kadowaki S, et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol. 2014;13:84.
17. Wang XH, Dou LZ, Gu C, Wang XQ. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pac J Trop Med. 2014;7:55-62.
18. Nabipour I, Larijani B, Beigi S, et al. Relationship among insulinlike growth factor I concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women: a population-based study. Menopause. 2008;15:934-939.
19. WHO MONICA Project, MONICA manual. Available at: http://www.thl.fi/publications/monica/manual/index.htm; 1999.
20. Prineas RJ, Crow RS, Blackburn HW, eds. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. 2nd ed. London: Springer-Verlag; 1982.
21. Choudhury SR, Yoshida Y, Kita Y, Nozaki A. Association between electrocardiographic ischemic abnormalities and ischemic heart disease risk factors in a Japanese population. J Hum Hypertens. 1996;10:225-234.
22. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-1197.
23. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
24. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med. 2011;28:1194-2000.
25. Shang FJ, Wang JP, Liu XT, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers. 2011;16:657-662.
26. Kadoglou NP, Tahmatzidis DK, Giannakoulas C, et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: KOZANI STUDY. J Cardiovasc Med (Hagerstown). 2015;16:341-346.
27. Saely CH, Leiherer A, Muendlein A, et al. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. Atherosclerosis. 2016;244:38-43.
28. Duan XY, Xie PL, Ma YL, Tang SY. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids. 2011;41:1223-1231.
29. Xie H, Xie PL, Wu XP, et al. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovas Res. 2011;92:296-306.
30. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring). 2011;19:1552-1559.
31. Zhou JY, Chan L, Zhou SW. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol. 2014;12:136-43.
32. Kazama K, Okada M, Hara Y, Yamawaki H. A novel adipocytokine, omentin, inhibits agonists-induced increases of blood pressure in rats. J Vet Med Sci. 2013;75:1029-1034.
33. Maruyama S, Shibata R, Kikuchi R, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem. 2012; 287:408-417.
34. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol. 2012;686:116-123.
35. Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012;4:37.
36. Sattar N, Watt P, Cherry L, Ebrahim S, Davey Smith G, Lawlor DA. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J Clin Endocrinol Metab. 2008;93:1846-1849.
37. Ogorodnikova AD, Wassertheil-Smoller S, Mancuso P, et al. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study. Stroke. 2010;41:1376-1381.
38. Macfarlane PW, Norrie J. Looking for prognostic information in the ST-T segment - is it really worth it? J Electrocardiol. 2004;37(suppl):209-213.
39. Lindblad U, Langer RD, Wingard DL, Thomas RG, Barrett-Connor EL. Metabolic syndrome and ischemic heart disease in elderly men and women. Am J Epidemiol. 2001;153:481-489.
40. Nabipour I, Amiri M, Imami SR, et al. The metabolic syndrome and nonfatal ischemic heart disease; a population-based study. Inter J Cardiol. 2007;118:48-53.